Difference between revisions of "Umbralisib (Ukoniq)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 5: Line 5:
 
*[[Follicular lymphoma]]
 
*[[Follicular lymphoma]]
 
*[[Marginal zone lymphoma]]
 
*[[Marginal zone lymphoma]]
 +
 +
==Patient drug information==
 +
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf Umbralisib (Ukoniq) Medication Guide]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf Umbralisib (Ukoniq) Medication Guide]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==

Revision as of 22:45, 8 March 2021

Mechanism of action

Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: TGR-1202
  • Brand name: Ukoniq